KRYS
Krystal Biotech Inc
NASDAQ: KRYS · HEALTHCARE · BIOTECHNOLOGY
$305.71
+3.04% today
Updated 2026-05-08
Market cap
$8.75B
P/E ratio
39.72
P/S ratio
20.96x
EPS (TTM)
$7.47
Dividend yield
—
52W range
$123 – $303
Volume
0.3M
WallStSmart proprietary scores
65
out of 100
Grade: B
Buy
Investment rating
8.3
Growth
A9.0
Quality
A+9.0
Profitability
A+4.7
Valuation
C4/9
Piotroski F-Score
Moderate
8.0
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →195 stocks currently score above 75
Price targets
Analyst target
$318.22
+4.09%
12-Month target
$205.44
-32.80%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy10 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 7.95 — safe zone
+ Profit margin 53.90% — above average
+ Free cash flow $73.23M — positive
+ Revenue growth 31.90% QoQ
+ Debt/equity 0.01x — low leverage
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $50.70M | $290.51M | $389.13M | $417.30M |
| Net income | $-139.97M | $10.93M | $89.16M | $204.83M | $55.93M |
| EPS | — | — | — | — | $7.47 |
| Free cash flow | $-153.55M | $-100.60M | $119.18M | $188.91M | $73.23M |
| Profit margin | — | 21.56% | 30.69% | 52.64% | 53.90% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-04 | KRISHNAN, SUMA | Sale | 6,000 | $265.16 |
| 2026-03-04 | KRISHNAN, SUMA | Sale | 4,852 | $264.64 |
| 2026-03-04 | KRISHNAN, SUMA | Sale | 3,667 | $260.37 |
Peer comparison
Smart narrative
Krystal Biotech Inc trades at $305.71. representing a P/E of 39.72x trailing earnings. Our Smart Value Score of 65/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 7.95, it sits in the safe zone. TTM revenue stands at $417.30M. with profit margins at 53.90%.
Frequently asked questions
What is Krystal Biotech Inc's stock price?
Krystal Biotech Inc (KRYS) trades at $305.71.
Is Krystal Biotech Inc overvalued?
Smart Value Score 65/100 (Grade B, Buy).
What is the price target of Krystal Biotech Inc (KRYS)?
The analyst target price is $318.22, representing +4.1% upside from the current price of $305.71.
What is Krystal Biotech Inc's revenue?
TTM revenue is $417.30M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
7.95 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio20.96x
ROE19.90%
Beta0.50
50D MA$263.45
200D MA$220.53
Shares out0.03B
Float0.02B
Short ratio—
Avg volume0.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—